Fox Run Management, L.L.C. Ionis Pharmaceuticals Inc Transaction History

Fox Run Management, L.L.C.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$36.45 - $47.7 $197,595 - $258,581	5,421 New	5,421 $258,000
Q4 2023 Feb 13, 2024	BUY	$43.39 - $51.63 $402,268 - $478,661	9,271 New	9,271 $469,000
Q2 2022 Aug 12, 2022	BUY	$31.71 - $43.0 $218,577 - $296,399	6,893 Added 76.13%	15,947 $590,000
Q1 2022 May 10, 2022	BUY	$29.88 - $37.04 $51,692 - $64,079	1,730 Added 23.62%	9,054 $335,000
Q4 2021 Feb 09, 2022	SELL	$25.61 - $35.1 $435 - $596	-17 Reduced 0.23%	7,324 $223,000
Q3 2021 Nov 15, 2021	BUY	$33.54 - $40.55 $246,217 - $297,677	7,341 New	7,341 $246,000
Q1 2018 Apr 17, 2018	SELL	$44.08 - $55.05 $363,660 - $454,162	-8,250 Closed	0 $0
Q4 2017 Jan 18, 2018	BUY	$50.3 - $64.39 $123,235 - $157,755	2,450 Added 42.24%	8,250 $415,000
Q3 2017 Oct 23, 2017	BUY	$45.56 - $59.57 $264,248 - $345,506	5,800	5,800 $294,000

403

136M

862K

582K

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $5.35B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.